The WHO Medicines Strategy 2008-2013 Richard Laing Based on materials produced by Hans V. Hogerzeil, Essential Medicines and Pharmaceutical Policies November.

Slides:



Advertisements
Similar presentations
A 2030 framework for climate and energy policies Marten Westrup
Advertisements

THE GHANA POVERTY REDUCTION STRATEGY Integration and Progress of Environmental Issues By Winfred Nelson NDPC November
World Health Organization Information, Evidence and Research The Road to Bamako Tim Evans Assistant Director General, WHO Scaling Up Research and Learning.
Putting the recommendations into action. 2 Promises made in context Global Strategy for Women's and Children's Health More than 200 commitments from a.
Comprehensive Review of National Development Strategies Lesotho.
19-20 September 2013, IBGE, Rio de Janeiro, Brazil
Situation Analysis: Programme Communication in West & Central Africa Neil Ford Regional Chief, Programme Communication West and Central Africa Dakar: 8.
How were the de- institutionalization targets and activities defined in planning and strategic documents in 4 countries? How were they applied, monitored.
HIV/AIDS, Schools and Education A Global Strategy Framework Prepared by the UNAIDS Inter-Agency Working Group on HIV/AIDS, Schools and Education.
Millennium Development Goals (MDGs) Report of progress and analytical paper Diana Alarcón November 2003.
Evaluation of ESF Support for Roma integration Dominique Bé EURoma, 10 November 2011, Budapest.
of EU Development Policy
Workshop on Sector Approaches in the Context of EU Integration Sarajevo, Bosnia and Herzegovina March 2010 Debriefing of the Workshop on Sector Approaches.
Water seminar Brussels, July 2010 Water, sanitation and the other MDGS A. Liebaert, DG DEV/B/1.
Cedefop Handbook on National Guidance Forums – Purpose and rationale Mr Mika Launikari Cedefop, Thessaloniki, 4-5 June 2008.
DISABLING BARRIERS – BREAK TO INCLUDE WORLD REPORT ON DISABILITY.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.
WHO-Technical Briefing Seminar | 03 November 2010 Gilles Forte 1 |1 | WHO Technical Briefing Seminar Geneva November WHO Collaboration with.
Reducing Child Mortality: Focusing on Equity Kim Mulholland.
Local Immigration Partnerships: Systems Planning to Help People.
The Role of Sport-for-Development. Sport for Development can be defined as using the power of sport to build on the values of development, such as equity,
15-18 Nov 2011Regional CH PM Meeting, Nepal1 Managing Programmes to Improve Child Health Overview CAH-SEARO.
Fostering R&D and Promoting Access to Medicines (for all) From Alma Ata, via Doha to Geneva (in 10 minutes) Bellagio, Italy October 2007 Ellen ‘t.
The Global Laboratory Initiative Assisting countries to implement the WHA resolution on MDR-TB Karin Weyer, WHO-STB, GLI secretariat John Ridderhof, CDC,
Strategies for Working with Countries – Regional and Sub-Regional Perspective and Experiences Essential Drugs and Medicines Policy WHO South-East Asia.
Renewing Health Canada’s strategy against TB for First Nations on-reserve Provincial Primary Care Tuberculosis Education Day October 28, 2011 Presented.
£ Fair Funding RAPs Quality Staff Supply and development Services (SSE) SEND & VL Early Help and Specialist Services Compact Oversee quality, Value for.
Scaling up Community based Management of Acute Malnutrition; but doing it differently Anne Philpott, Nutrition Adviser Abigail Perry, Humanitarian Adviser.
Making the UN “fit for purpose” for the new sustainable development agenda John Hendra December 2014.
Integrating the needs of young people into the Second National Economic Empowerment and Development Strategy (NEEDS 2) Dabesaki Mac-Ikemenjima Representative.
Supporting Integrated Health Systems Strengthening A CIDA Perspective.
Public health, innovation and intellectual property 1 |1 | WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Global Strategy and Plan.
IGWG process Gaudenz Silberschmidt, Switzerland Public Health, Innovation and Intellectual Property Global strategy and Plan of Action Dr Gaudenz Silberschmidt,
Public Health, Innovation and Intellectual Property Improving access to medicines through local production: Some New Development I P C Meeting, Copenhagen.
Process of Development of Five Year Strategic Plan for Child Health Development Dr Myint Myint Than Deputy Director (WCHD) Department of Health.
The SEEAW in the context of Integrated Water Resource Management and the MDGs Roberto Lenton Chair, Technical Committee Global Water Partnership.
African Health Leadership and Management Network (AHLMN) Plenary Overview of Business Plan.
MDGs, and WSSD Plan of implementation Ashbindu Singh Regional Coordinator Division of Early Warning & Assessment – North America United Nations Environment.
World Health Organization Department of Chronic Diseases and Health Promotion World Health Organization Global Perspective on Health Promotion Tang Kwok-cho.
REGIONAL ANALYSIS ON DISASTER RISK REDUCTION EDUCATION IN THE ASIA PACIFIC REGION IN THE CONTEXT OF HFA PRIORITY 3 IMPLEMENTATION Bangkok, March 2009 Prepared.
Department of Technical Cooperation for Essential Drugs and Traditional Medicine (TCM) Roles and responsibilities in implementing the WHO Medicines Strategy.
Sectoral analysis in development OPVK Inovace výuky geografických studijních oborů, CZ.1.07/2.2.00/
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
Brussels, May 2008MDA Update, RHSC membership meeting Market Development Approaches Working Group Update November 2007 – May 2008 Ben Light MDAWG Leader,
WHO support to countries in the area of medicines example of the African Region WHO/EDM Drug Action Programme.
WHO/OMS Improving and increasing investments in the health outcomes of the poor Macroeconomics and Health in context Dr. Sergio Spinaci, WHO Senegal, February.
Medicines systems: Convergence for access Dr Socorro Escalante WHO Country Office for Viet Nam 1.
EuropeAid Implementing Development Aid The Water Supply and Sanitation Sector S. Dalamangas EuropeAid Cooperation Office Athens October 2010.
The Millennium Development Goals (MDGs) A Primer JPO Regional Workshop Nairobi, 28 May 2002.
TBS 2008-H. Tata & M. Babaley Mapping and In-depth Assessment of Medicines Procurement and Supply Systems WHO Technical Briefing Seminar 17 th -21 st November.
Repositioning Family Planning in West Africa Repositionnement de la Planification Familiale en Afrique de l’Ouest Sponsored by: U.S. Agency for International.
Panel on mainstreaming disability in MDG processes New York, 3 September 2009 Mainstreaming disability in the MDG process Maria Martinho United Nations.
HIV AND INFANT FEEDING A FRAMEWORK FOR PRIORITY ACTIONS.
The WHO Medicines Strategy Kees de Joncheere Essential Medicines and Health products November 2012.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
Octavian Thursday, September 25, 9:00 am OUTLINE 1. Aims, Objectives and Expected Outputs 2. Global and Regional Situation 3. Challenges to Sustainability.
The WHO Medicines Strategy , and the Global Action Plan on Public Health, Innovation and Intellectual Property Hans V. Hogerzeil, MD, PhD, FRCP.
9th World Conference on Injury Prevention and Safety Promotion WHO programmes on violence and injury prevention: future plans Etienne Krug Director, Violence.
1 Ministry of Social Protection, Family and Child 27 th September 2007.
Department of Social Development National Conference Early Childhood Development Conference “Tshwaragano Ka Bana” 29th March 2012 The National Integrated.
SPECIAL SESSION COUNTDOWN TO 2015 IN ETHIOPIA SIX BUILDING BLOCKS OF THE HEALTH SYSTEM: PROGRESS TOWARDS THE INTEGRATION IN ETHIOPIA Dereje Mamo Tsegaye.
UNICEF Social Protection Work an overview Show and Tell on Social Protection Bonn, 2011 UNICEF and social protection – Rationale: Equity approach Social.
World Health Organization
The WHO Medicines Strategy , and
WHO Medicines Work in Countries: The Kenya Example
Review of integrated PSM resources and tools and introduction to group work Upjeet Chandan ICCM FTT 17th February 2016.
Access to Essential Medicines
A year of progress on global and country coordination on PHC
Presentation transcript:

The WHO Medicines Strategy Richard Laing Based on materials produced by Hans V. Hogerzeil, Essential Medicines and Pharmaceutical Policies November 2011

2 WHO Essential Medicines Outline of the presentation n Trends in the pharmaceutical scene, strategic landscape n The WHO Medicines Strategy for : ä Access ä Quality ä Rational use n The Essential Medicines Family n Potential areas of collaboration

3 WHO Essential Medicines Trends in global pharmaceutical situation, new challenges for (1) n Recognition that vertical programmes need an integrated approach with horizontal health systems, supply systems n More interest in medicine quality and quality assurance systems; this implies the need for practical global standards and support to national regulatory agencies n Several new global funding mechanisms for essential medicines; these need global health policy direction, global standards and technical support from WHO n More players and partnerships, complicating the landscape; these need a multi-stakeholder ("MOH-plus") approach and coordination at country level

4 WHO Essential Medicines Trends in global pharmaceutical situation, new challenges for (2) n IPR interest shifting from global TRIPS discussion towards technical support to countries; new focus on innovation and public health, inter-governmental process n More interest of Middle Income Countries in medicine issues such as pricing, reimbursement and quality; need for relevant standards and high-level technical support n DG priorities (PHC, Africa, women) implies the need to re- shape PHC, renewed focus on public sector and essential medicines, new focus on reimbursement schemes n Recent WHA resolutions (prices, IPR, rational use, medicines for children); this implies the need for fundraising and recruitment to expand work in these areas

5 WHO Essential Medicines Example of impact of earlier Medicine Strategies:

6 WHO Essential Medicines Examples of country progress in supply:

7 WHO Essential Medicines WHO Medicines Strategy Strategic landscape n Experiences from and Medicine Strategies n Millennium Development Goals n WHO Medium Term Strategic Plan ä Strategic Objective 11 covers access, quality, rational use n Recent WHA resolutions ä Rational use, EMs for children, IGWG Strategic Plan n Stated priorities of the new Director-General ä MDGs, Universal Access through PHC/Health Systems; evidence-based policies; partnerships; health-in-all-policies n Other country needs (if not included in above)

8 WHO Essential Medicines Strategic landscape: Medicine-related Millennium Development Goals MDGsMedicine-related targets by 2015Medicine-related indicators Goal 4: Reduce child mortality Target 5: Reduce <5 mortality rate by 2/313. Under-five mortality rate 14. Infant mortality rate Goal 5: Improve maternal health Target 6: Reduce maternal mortality by ¾16. Maternal mortality ratio Goal 6: Combat HIV/AIDS, malaria and other diseases Target 7: Reversed spread of HIV/AIDS18. HIV prevalence in pregnancy 19. % condom use in contraception Target 8: Reversed malaria incidence21. Malaria prevalence and death rates 22. Use of malaria prevention and treatment 23. TB prevalence and death rates 24. Proportion cured with DOTS Goal 8: Develop a global partnership for development Target 12: Open, rule-based, predictable, non-discriminatory trading and financial system Target 13: Address special needs of least developed countries Target 17: In cooperation with pharmaceutical companies, provide access to affordable, essential drugs in developing countries 46: Proportion of population with sustainable access to affordable essential drugs

9 WHO Essential Medicines New standard set of indicators for measuring access for WHO/MTSP, UNDP/MDG8 Gap Analysis and Lancet assessment Government commitment: n Access to essential medicines/technologies as part of the fulfillment of the right to health, recognized in the constitution or national legislation (S) n Existence and year of a published national medicines policy (S) Rational selection: n Existence and year of a published national list of essential medicines (S) Affordable prices: n Legal provisions to allow generic substitution in private sector (S) n Median consumer price ratio of 30 selected EMs in pub/private facilities (P) n Percentage mark-up between manufacturers' and consumer price (P) Sustainable financing: n Public and private per capita expenditure on medicines (P) n % of population covered by national health service or health insurance (P) Reliable systems: n Average availability of 30 selected EMs in public/private health facilities (O) (Quantified intuition)

10 WHO Essential Medicines WHO strategic directions in medicines 1: Policy, access (1) n National medicine policies: Continue national policies; new focus on comprehensive PHC, health insurance; in countries more focus on strategic components of medicines policy n Intellectual Property Rights: Continue technical support; new focus on IPR and innovation, new approach to medicine patents n Traditional medicine: Continue support on regulating quality and safety; new focus on integrating with allopathic medicine policies, promoting evidence on efficacy, regulating products and professionals n Access: New focus on separate access indicators and on activities to promote availability, price and affordability

11 WHO Essential Medicines WHO strategic directions in medicines 1: Policy, access (2) n Comprehensive supply systems: Continue promotion of best practices; new focus on private sector, transparency and regulatory approach n Transparency and good governance: New policy guidance on transparency and good governance in pricing, procurement, registration; use to strengthen comprehensive systems n Information and planning: Improve indicators and household surveys; new link with NHAs, IMS-data, IEP surveys to create package of country data and improve planning; new focus on sex- disaggregated statistics n New global funding mechanisms: Continue country support; new focus on guidance and technical support to global funds

12 WHO Essential Medicines WHO strategic directions in medicines 2: Quality n Nomenclature: Continue INN and other nomenclatures; new focus on methods to assign names to biological products n Controlled drugs: Continue treaty obligations on scheduling; new focus on improving access to controlled medicines n Quality: Continue normative work (Expert Committees); new focus on missing EMs for priority diseases and children; tools for assessment of regulatory and supply agencies; regional coordination (link to economic blocs) n Prequalification: Continue PQ of priority medicines; new focus on QClabs, APIs, CROs; advice to diagnostics, RH commodities, vaccines; strong focus on capacity building n Combating counterfeits: Continue developing IMPACT partnership; focus on practical implementation of strategy

13 WHO Essential Medicines WHO strategic directions in medicines 3: Rational use n Selection: Continue evidence-based Model List and EM Library; new focus on EMs for children, methodological guidance within WHO (Guidelines Development Group) n Rational use: Continue global database; new focus on national RU programmes (situation analysis, multi-stakeholder approach, comprehensive health systems, national RU body); new focus on antimicrobial resistance and adherence to chronic treatment; fund- raising n Pharmacovigilance: Continue global ADR programme; new focus on disease-specific cohort methods for priority diseases (malaria, HIV) and active steering of new global interest in pharmacovigilance

14 WHO Essential Medicines World Medicines Situation 2011 n The third edition of the World Medicines Situation Report brings together new data on 24 key topics relating to pharmaceutical production and consumption, innovation, regulation and safety - in one place. n Topics include selection, procurement, supply management, rational use, financing and pricing. Cross-cutting chapters cover household medicines use, access and human rights, good governance, human resources and national medicines policies. n Each chapter of this report is written by a different author. Chapters are being published electronically, in batches, between April and December The new report updates the 1988 and 2004 reports.

15 WHO Essential Medicines World Medicines Situation 2011 n Introduction Introduction n Global health trends: global burden of disease and pharmaceutical needs n Pharmaceutical consumption n Medicine expenditures Released August 2011 Medicine expenditures n Financing medicines n Medicines prices, availability and affordability Released April 2011 Medicines prices, availability and affordability n Access to medicines at the household level (access to health care and medicines: burden of expenditures and risk protection) n Research and development of medicines n Intellectual property, trade and medicines n Regulation of medicines n Quality of medicines: the challenge of globalization n Pharmacovigilance and Safety of Medicines Released August 2011 Pharmacovigilance and Safety of Medicines n Selection of Essential Medicines Released August 2011 Selection of Essential Medicines n Rational use of medicines Released April 2011 Rational use of medicines n Medicines Information and regulation of promotion n Procurement of Medicines Released August 2011 Procurement of Medicines n Storage and supply chain management of medicines n Traditional medicines: global situation, issues and challenges Released April 2011 Traditional medicines: global situation, issues and challenges n Access to controlled medicines Released April 2011 Access to controlled medicines n Good governance of pharmaceutical Sector Released April 2011 Good governance of pharmaceutical Sector n Human resources in pharmaceuticals n Access to Essential Medicines as Part of the Right to Health Released August 2011 Access to Essential Medicines as Part of the Right to Health n National medicines policy n Conclusion

16 WHO Essential Medicines Global Medicines Family n Geneva: Department of Essential Medicines and Pharmaceutical Policies EMP (about 100 staff) n Six regional offices: 2-5 professionals per office n 40 of 100 WHO country offices have full-time pharmaceutical policy experts (about half of them funded through EC funds) n Many external networks: ä Six Expert Advisory Panels (quality, policy, narcotics, selection, etc) ä About 50 WHO Collaborating Centres (centres of excellence) ä Regulators, inspectors, laboratories, INRUD, HAI, safety, INN, pricing ä E-drug, Re-med, e-farmacos, india-drug, etc (over 8000 subscribers) ä Interagency Pharmaceutical Coordination (all UN agencies)

17 WHO Essential Medicines WHO/EMP has many implementation channels MOHOutside MOH: Drug regul. agency, insurance, collab.centers, universities, missions, NGOs, consumers Regional Offices WHO: HIV, MAL, TB, RH, MSD,CAH, HSS (Trad Med) UN: UNICEF, UNAIDS, UNFPA, WBank, GFATM, WIPO, etc Country Offices WHO Department of EMP NGOs: MSF, HAI, MSH, JSI churches, networks, WMA, FIP, IGPA, IFPMA, WSMI, etc National programmes for health professionals, patients and consumers IPC

18 WHO Essential Medicines Essential Medicines and Pharmaceutical Policies (EMP) MAR Medicine Access and Rational Use C.Ondari, Coordinator QSM Quality and Safety: Medicines L.Rägo, Coordinator Carissa Etienne Acting Director Selection of ess. medicines Pricing and financing Supply management Rational Use INN programme Quality Assurance Safety and Efficacy Prequalification Assessment Inspection Capacity building Regulatory support Controlled medicines Blood products and related biologicals MPC Medicine Programme Coordination G.Forte, Coordinator Incorporating MIE Country programme coordination & support Policy guidance Country profiles Good governance & MeTA EHT Essential Health Technology & Medical devices Acting Coordinators Prequalification of Diagnostics Policy guidance on Technology Country Surveys HTA

19 WHO Essential Medicines New areas of work (currently unfunded) n Combating counterfeit medicines n Access to controlled medicines (analgesics, drug abuse) n Promoting rational medicine use, antimicrobial resistance n Access to therapeutic sera (antirabies, snake, scorpions) n Production of global reference standards Recently (partly) funded n Essential Medicines for Children (Gates Foundation) n Pharmacovigilance for new EMs for HIV (Gates Foundation) n Good Governance for Medicines (Germany)

20 WHO Essential Medicines Conclusion: Essential Medicines in November 2011 Good news: n World Medicines Strategy nearly complete n Better access indicators now used for UN/MDGs, MTSP, others n Global norms/standards, prequalification, WHO/HAI pricing methods, 80 country projects and innovative public health thinking lead to solid international reputation, trust by Member States Bad news: n WHO Medicines Programme has nearly become an NGO ä RB 12-20%, CVC 10-12%, Specified Project Funding >70% ä Government contributions stable, foundations strongly increasing ä No donor interest in rational use, comprehensive country support